Overview
With $400 million in assets under management, H.I.G. BioHealth Partners invests in a broad range of healthcare companies across multiple sectors and stages of development. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs more >
Portfolio
Recent News
- Thu, Jan 25th, 2018 — TOBA II BTK Trial Enrollment Ahead of Schedule for the Tack Endovascular System® in Below…
- Tue, Jan 9th, 2018 — CardioFocus® Announces Expanded Partnership with Japan Lifeline
- Wed, Nov 29th, 2017 — CardioFocus® Completes Successful Controlled U.S. Commercial Launch of the HeartLight® System
- Mon, Nov 27th, 2017 — Apollo Endosurgery Receives FDA Clearance for OverStitch™ Sx Endoscopic Suturing System
- Wed, Nov 22nd, 2017 — FDA Approves RxSight’s Light Adjustable Lens, First IOL to Enable Refractive Correction…
- Thu, Nov 16th, 2017 — David C. Pacitti Joins Apollo Endosurgery Board of Directors
- Wed, Sep 27th, 2017 — CardioFocus® Announces European CE Mark Approval of the Next-Generation HeartLight® Excalibur…
- Thu, Aug 31st, 2017 — Apollo Endosurgery Announces 20-year LAP-BAND® Outcomes Data Presented at 22nd IFSO World…
- Tue, Aug 22nd, 2017 — Iconic Therapeutics Appoints Brandon Smith Chief Operating Officer
- Mon, Jul 31st, 2017 — CardioFocus® Receives Approval for HeartLight® Endoscopic Ablation System from the Japanese…